The 42-Day Protocol Is the Beginning, Not the End
When a patient completes OPTM's 42-day protocol with excellent results — pain eliminated, mobility restored, biomarkers normalised — there is a natural temptation to treat the outcome as permanent without further effort. In many cases, this is reasonable: 88% of patients maintain improvement at 12 months without ongoing medical intervention.
But maintaining healthy joints over the long term requires understanding what created the joint problem in the first place — and avoiding the return of those conditions.
The metabolic drivers of joint degeneration do not disappear after treatment. Elevated environmental pollution exposure, chronic psychological stress, sedentary behaviour, nutritional deficiencies, and poor sleep quality can all gradually rebuild the inflammatory environment that OPTM's protocol dismantled. The 12% of patients who experience relapse at 12 months almost universally have identifiable lifestyle triggers — and the relapse is almost always reversible.
Our post-treatment programme is built around three pillars:
Anti-inflammatory nutrition: The dietary pattern most protective against joint inflammation is broadly consistent with a Mediterranean-style diet — abundant colourful vegetables, omega-3 rich fish and seeds, olive oil, legumes, and whole grains. Conversely, ultra-processed foods, refined carbohydrates, and excessive saturated fat promote the inflammatory cytokine production that drives joint degeneration. We provide personalised dietary guidance based on your specific biomarker profile.
Strategic movement: The body's joints are designed to move. Sustained immobility reduces synovial fluid circulation, impairs cartilage nutrition (which has no blood supply and relies on fluid movement for oxygen and nutrients), and accelerates muscle atrophy that increases joint loading. Our post-treatment movement programme specifies the type, frequency, and intensity of activity that best supports long-term joint health for your specific condition and fitness level.
Periodic biomarker monitoring: We recommend a biomarker check at 3, 6, and 12 months post-treatment — and annually thereafter. This monitoring catches early signs of inflammatory marker elevation before they translate into symptoms, allowing us to intervene early with a brief protocol adjustment. Think of it as a joint health MOT.
Related Clinical Resources
